USPTO serial 88788969
ALKERMES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 13, 2022
- Examiner
- DANG, PETER T
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ALKERMES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Waltham, MA, US
Waltham, MA, US
Waltham, MA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Norm J. Rich
Norm J. Rich FOLEY & LARDNER LLP3000 K STREET, N.W.SIXTH FLOORWASHINGTON, DC 20007Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, compounds for use in treating addiction, substance abuse and dependence, diseases and disorders of the central nervous system, cancer, reward disorders, psychiatric and neurodegenerative diseases and disorders in the nature of schizophrenia, depression, major depressive disorder, stress, anxiety, treatment resistant depression, bipolar depression, and bipolar disorder; pharmaceutical preparations for use in treating cardiovascular diseases and metabolic diseases; pharmaceutical preparations for the mitigation of weight gain and the treatment of metabolic diseases and dyslipidaemia; Pharmaceutical preparations, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, psychiatric and neurodegenerative diseases, cardiovascular diseases and metabolic diseases; pharmaceutical preparations in the nature of compounds, namely, small molecules and chemical compounds for use in opioid modulation for treating opioid use disorders | ACTIVE | Jan 21, 2022 |
| 035 | Administration and management of an annual competitive award program in the nature of research grants for scientific research; Logistics management in the field of medication, namely, business services in the nature of supporting the coordination of medication delivery to avoid product delivery delays; providing business administration information to patients and health care providers about medication reimbursement options regarding reimbursement procedures; providing information about pharmaceutical services, namely, providing information about processing online prescription orders in retail pharmacies regarding pharmacy authorization in the nature of prescription fulfillment and approval instructions for delivery of medication in the nature of accepting payment terms; appointment reminder services being support services for patients and for health care providers on behalf of their patients | ACTIVE | May 4, 2018 |
| 036 | Providing grants to organizations dedicated to patient focused medical research; funding service awards, namely, providing grants to patient advocacy groups and institutions for the treatment and management of diseases including, but not limited to, addiction and central nervous system disorders; Providing insurance information about pharmacies, namely, providing a database featuring information about insurance coverage for pharmaceuticals in the nature of pharmacy selection based on patient health plan coverage requirements; providing insurance information about pharmaceutical coverage by patient health plans; providing insurance administration information to patients and health care providers about medication reimbursement options; insurance services, namely, insurance eligibility review and verification being support services for patients and for health care providers on behalf of their patients, namely, providing health benefit verification services to determine coverage of medication treatment in the health industry; financial administration of medication reimbursement programs being support services for patients and for health care providers on behalf of their patients, namely, coordinating medication reimbursement programs | ACTIVE | Sep 12, 2016 |
| 044 | Providing educational information in the field of medication treatment to health care providers and patients; providing educational information about pharmaceutical products relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals | ACTIVE | Oct 23, 2017 |
| 045 | Support services for health care providers and their patients in the nature of providing patient advocate and case management services, namely, coordinating the procurement of medication in the nature of coordinating with pharmacies to facilitate prescription fulfillment; providing patient advocate and case management services in the nature of support services for patients and for health care providers on behalf of their patients, namely, coordinating the procurement and administration of medication in the nature of locating health care providers that can prescribe and/or administer prescribed medication | ACTIVE | Oct 23, 2017 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Alkermes, Inc.
- Other trademarks owned by Alkermes, Inc.
- Other trademarks owned by Alkermes, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named ALKERMES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 24, 2026 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 13, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 13, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 9, 2022 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Nov 8, 2022 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Nov 8, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 7, 2022 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Nov 7, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Nov 7, 2022 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 28, 2022 | IUAF | USE AMENDMENT FILED | — |
| Oct 28, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Oct 28, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 28, 2022 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| May 7, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 5, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| May 5, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 5, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 18, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 16, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Nov 16, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Nov 16, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 1, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 29, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 29, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 29, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 17, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 22, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 22, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 2, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 17, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 7, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 6, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 6, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 28, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 28, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 28, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 28, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 11, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 11, 2020 | NWAP | NEW APPLICATION ENTERED | — |